Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1CNS 1Breast 1

Conditions

Neoplasms 2Glioblastoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 40Cisplatin 32Radiotherapy 22Cetuximab 22Radiotherapy, Intensity-Modulated 15Docetaxel 12Nivolumab 11Paclitaxel 10Fluorouracil 10Carboplatin 8Radiosurgery 6epacadostat 5Radiation 5spartalizumab 4avelumab 4Surgical Procedures, Operative 4Radiotherapy, Conformal 4Immunoglobulin G 4Biopsy 4ribociclib 3durvalumab 3bempegaldesleukin 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Everolimus 3Erlotinib Hydrochloride 3Disulfides 3Cyclophosphamide 3Albumin-Bound Paclitaxel 3utomilumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Squamous Cell Carcinoma of Head and Neck × depatuxizumab mafodotin × Clear all
NCT02365662 2018-03-30

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

AbbVie

Phase 1 Terminated
46 enrolled
BreastCNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡